biotech

Beyond Rising Deaths, Wuhan Coronavirus Already Hits China, US, Global Economies

The most recent coronavirus outbreak that originated in Wuhan in the Hubei province of China has become more deadly and is much less contained than global health officials would have ...
Read Full Story »

How Earnings Will Dictate Biotech Sector’s Fate in 2020

So far in 2020, the overall sentiment in the market still seems good following a strong finish to 2019. This is especially true among biotechnology stocks. The biotechs experienced large ...
Read Full Story »

This Biotech Could Make a Big Splash With the Coronavirus Scare

The newest coronavirus out of China has resulted in a rising interest in biotechs that may be able to produce a vaccine or treatment with a short turnaround. We’ve seen ...
Read Full Story »

Are Investors Overreacting to This Achromatopsia Study?

Applied Genetic Technologies Corp. (NASDAQ: AGTC) shares were crushed early Thursday after the firm reported interim data from its midstage trial in patients with achromatopsia. While the company says that ...
Read Full Story »

Why This Cardiovascular Disease Study Could Be Huge

Akcea Therapeutics Inc. (NASDAQ: AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ: IONS) each made handy gains on Wednesday after they reported midstage results for their cardiovascular disease study. Specifically, the results ...
Read Full Story »

Some Great News for Potential Alzheimer’s Treatment

It may be unusual to see a stock rise close to 100% without a corporate buyout, but in biotech and emerging pharmaceutical companies gains of that size can occur simply ...
Read Full Story »

China’s Coronavirus Could Prompt Buying Frenzy in These Biotech Stocks

China is facing an outbreak of the coronavirus, which may have spread to a few other countries in East Asia. Although less than 300 infections have been reported, there are ...
Read Full Story »

FDA Fast Track on Lung Cancer Treatment Brings Exponential Gains for This Microcap Stock

When companies see their shares rise by 100% or more in a single day, it's usually because of a buyout or an extremely positive change in a company's future prospects. ...
Read Full Story »

Winning Ideas in Biotech/Pharma After JPMorgan Healthcare Conference

For health care investors, 2020 looks like a potentially good year after an especially fruitful JPMorgan Healthcare Conference this past week. In fact, brokerage firm Janney spent last week visiting ...
Read Full Story »

This Week’s Biggest Biotech Movers

As the biotechnology group is pushing near all-time highs, this past week played host to a huge number of biotech movers. 24/7 Wall St. has picked a few of these ...
Read Full Story »

What’s Next for Durect After FDA Posimir Vote

Durect Corp. (NASDAQ: DRRX) shares dropped early on Friday after the U.S. Food and Drug Administration Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) announced its vote on Posimir, the ...
Read Full Story »

Are Neon Therapeutics’ Shareholders Getting Enough in the Buyout?

Neon Therapeutics Inc. (NASDAQ: NTGN) shares shot up on Thursday after the firm announced that it will be acquired by BioNTech SE (NASDAQ: BNTX). The question is: Are Neon Therapeutics ...
Read Full Story »

Why This Opioid Painkiller Is Killing Nektar Therapeutics Stock

Nektar Therapeutics (NASDAQ: NKTR) shares were crushed on Wednesday after the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management ...
Read Full Story »

Does FDA Decision Mean a Bright Future for This Flu Vaccine?

Novavax Inc. (NASDAQ: NVAX) shares jumped on Wednesday after the U.S. Food and Drug Administration (FDA) granted a Fast Track Designation for NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate, ...
Read Full Story »

Why Aquestive Therapeutics’ Seizure Treatment May Get Butted Out

Aquestive Therapeutics Inc. (NASDAQ: AQST) shares lost nearly a third on Monday after the firm received an update from the U.S. Food and Drug Administration (FDA). The long and short ...
Read Full Story »